Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Accumulated Expenses (2022 - 2025)

CervoMed (CRVO) has disclosed Accumulated Expenses for 9 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 35.23% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, up 35.23% year-over-year, with the annual reading at $3.2 million for FY2025, 35.23% up from the prior year.
  • Accumulated Expenses hit $3.2 million in Q4 2025 for CervoMed, down from $3.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.3 million in Q3 2025 to a low of $206675.0 in Q4 2022.
  • Historically, Accumulated Expenses has averaged $1.1 million across 4 years, with a median of $487467.0 in 2023.
  • Biggest five-year swings in Accumulated Expenses: crashed 59.86% in 2023 and later skyrocketed 666.14% in 2024.
  • Year by year, Accumulated Expenses stood at $206675.0 in 2022, then skyrocketed by 49.54% to $309062.0 in 2023, then surged by 666.14% to $2.4 million in 2024, then soared by 35.23% to $3.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for CRVO at $3.2 million in Q4 2025, $3.3 million in Q3 2025, and $2.8 million in Q2 2025.